XML 42 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue from Contracts with Customers (Notes)
 12 Months Ended
Dec. 31, 2020
Revenue from Contracts with Customers [Abstract]  
Revenue from Contract with Customer [Text Block]
20. Revenue from Contracts with Customers

Disaggregation of Revenue

The Company disaggregated its revenue from contracts with customers by segment and geographic location as the Company believed it best depicted how the nature, amount, timing and uncertainty of its revenue and cash flows were affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the eight months ended August 31, 2020 and the year ended December 31, 2019:
Eight Months Ended August 31, 2020Year Ended December 31, 2019
(in thousands)Medical Devices
Pharmaceutical (1)
Medical Devices
Pharmaceutical (1)
Primary geographical markets:
North America$6,656 $10,093 $10,155 $26,034 
Europe2,078 13,008 3,438 22,816 
Asia4,137 6,378 11,536 6,243 
Other200 — 433 — 
Total revenue from contracts with customers (2)
$13,071 $29,479 $25,562 $55,093 
_______________
(1) The revenue from the Company’s Pharmaceutical segment for the eight months ended August 31, 2020 and the year ended December 31, 2019 is included in Loss from discontinued operations. For additional information, see Note 4, Discontinued Operations Classified as Assets held for sale.

(2) The table above does not include lease revenue from the Company’s Medical Devices segment of $2.1 million and $5.2 million for the eight months ended August 31, 2020 and the year December 31, 2019, respectively. For additional information, see Note 10, Leases.
Contract Balances

The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:
(in thousands)December 31, 2019
Receivables, net$10,377 
Contract assets$3,512 
Contract liabilities$4,024 

Receivables, Net—Receivables, net, included amounts billed and due from customers. The amounts due are stated at their net estimated realizable value and are classified as current or noncurrent based on the timing of when the Company expects to receive payment. The Company maintained an allowance for doubtful accounts to provide for the estimated amount of receivables that would not be collected. The allowance was based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable. Receivables, net for our Pharmaceutical segment were classified as a current asset and included in Assets held for sale. See Note 4, Discontinued Operations Classified as Assets Held for Sale, for additional information.

Contract Assets—The Company’s contract assets represented revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales had not yet occurred. The Company’s contract assets were only attributable to the Pharmaceutical segment, and as such classified contract assets in Assets held for sale on the Company’s Consolidated Balance Sheet.

(in thousands)Medical DevicesPharmaceuticalTotal
Contract assets at December 31, 2019$— $3,512 $3,512 
Contract assets recognized— (6,730)(6,730)
Payments received— 8,562 8,562 
Contract assets disposed of— (5,344)(5,344)
Contract assets at December 31, 2020$— $— $— 

Contract Liabilities—The Company’s contract liabilities consisted of deferred revenue for products sold to customers for which the performance obligation had not been completed by the Company. The Company classified deferred revenue as current or noncurrent based on the timing of when it expected to recognize revenue. The noncurrent portion of deferred revenue was included in Other long-term liabilities on the Company’s Consolidated Balance Sheet. The Pharmaceutical segment deferred revenue was classified as a current liability and included in Liabilities held for sale on the Company’s Consolidated Balance Sheet.

(in thousands)Medical DevicesPharmaceuticalTotal
Contract liabilities at December 31, 2019$1,075 $2,949 $4,024 
Additions658 1,659 2,317 
Amounts recognized in revenue(851)(888)(1,739)
Contract liabilities disposed of(882)(3,720)(4,602)
Contract liabilities at December 31, 2020$— $— $—